By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ISA Pharmaceuticals 

J.H. Oortweg 19

Leiden    NL-2333 CH  The Netherlands
Phone: 31-71-33-22-310 Fax: 31-71-33-22-311



Company News
ISA Pharmaceuticals Obtains Broad Patent Protection In The US For Proprietary AMPLIVANT Platform And Compounds 4/19/2016 10:45:41 AM
ISA Pharmaceuticals’ Lead Product ISA101 Efficiently Engages The Immune System Against Virus-Induced Pre-Malignant And Malignant Lesions 4/14/2016 9:40:55 AM
Scientific Review Endorses ISA Pharmaceuticals’ Strategy To Overcome Immune Evasion In Cancer Immunotherapy 3/11/2016 9:09:47 AM
ISA Pharmaceuticals Appoints Gerben Moolhuizen As Chief Business Development Officer 1/5/2016 10:37:54 AM
ISA Pharmaceuticals’ ISA101 Studied In Phase II Combination Trial With Checkpoint Inhibitor Nivolumab 12/7/2015 11:43:17 AM
ISA Pharmaceuticals Release: Towards A Best Practice Approach In Cancer Immunotherapy: Cancer Vaccines Gain Momentum 7/28/2015 9:09:10 AM
ISA Pharmaceuticals Further Strengthens IP Position On Lead Compound ISA101 6/23/2015 8:20:14 AM
New Peer-Reviewed Publication Provides Further Insights Into Mechanism Of ISA Pharmaceuticals’ SLP Immunotherapeutics 5/12/2015 11:13:30 AM
ISA Pharmaceuticals Granted European Patent For The Intradermal Administration Of ISA101 3/24/2015 10:40:43 AM
ISA Pharmaceuticals Signs R&D Agreement With Shin Nippon Biomedical Laboratories 3/3/2015 2:31:22 PM